Ception Therapeutics Initiates Phase II/III Clinical Trial for Its – PR Newswire
MALVERN, Pa., March 5 /PRNewswire/ — Ception Therapeutics, Inc. announced today the initiation of a multi-center, Phase II/III clinical trial to evaluate reslizumab, a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5), for the
Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded – PR Newswire
COLLEGE PARK, Md., Oct. 16 /PRNewswire-USNewswire/ — A clinical trial conducted by University of Maryland School of Medicine researchers and CSA Medical Inc. may yield a breakthrough treatment for pre-cancerous and cancerous diseases of the
